Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Medical Costs at Medical Institutions Down 1.9%
September 3, 2001
- Toshiba: High-speed Multislice CT Scanners
September 3, 2001
- Minister-backed Panel to Propose Policies to Promote Drug Discovery
September 3, 2001
- Antacids Are Most Expensive in Tokyo: Inter-city Comparison of OTC Drug Prices
September 3, 2001
- PMSB Considers Introduction of Drug Master File System
September 3, 2001
- Kirin-do to Strengthen Dispensing Function
September 3, 2001
- ADR Reports on 6 Drugs Including Temocapril HCl Published
September 3, 2001
- Innovex to Establish Japan's 1st MR Syndicate Team Next Year: Mr Feldman
August 27, 2001
- Stage 2 Schedule Set for Quality Reevaluation of 249 Ingredients
August 27, 2001
- Genomic Analysis by Industry, Government, Academia Started
August 27, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
August 27, 2001
- Launching of Tarivid Generics Postponed Due to Patent Problems
August 27, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 27, 2001
- Nosan Corporation Ties Up with Midwest Research Institute
August 27, 2001
- Quality Reevaluation Enters Step 4 for 28 Ingredients
August 27, 2001
- MEDICAL DEVICE NEWS IN BRIEF
August 27, 2001
- Kirin Forms Research Alliance with Hyseq
August 27, 2001
- Use of Orange Book, Rx in Generic Name Recommended for Promotion of Generics: EAD Director
August 27, 2001
- Fujirebio, diaDexus Tie Up to Develop Cancer Diagnostic Agents
August 27, 2001
- Alendronate to Change Market for Osteoporosis
August 27, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…